Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05672459Phase 1Active Not Recruiting

A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Role: collaborator

NCT02818426Phase 1Completed

Universal Cancer Peptide-based Vaccination in Metastatic NSCLC

Role: collaborator

NCT04515043Phase 1Completed

EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)

Role: lead

NCT03265717Phase 2Terminated

DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia

Role: lead

NCT02301754Phase 1Completed

INVAC-1 Anti-Cancer hTERT DNA Immunotherapy

Role: lead

All 5 trials loaded